Name
GS1-09 (J): Sacituzumab Govitecan vs. Chemotherapy as First Therapy After Endocrine Therapy in HR+/HER2- (IHC 0, 1+, 2+/ISH-) Metastatic Breast Cancer: Primary Results From ASCENT-07 Commentary by: Prof. Shigehira Saji
Date & Time
Tuesday, December 2, 2025
Speakers
Virtual Session Link
Total Minutes
04:59
OnDemand Video URL